Jul 09, 2008 Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity Sensor. To break through the wire to form the electrode pair, a high precision micromilling machine (KERN MMP 2522,
Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and Label-free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity Sensor André A. Adams, Paul I. Okagbare, Juan Feng, Matuesz L. Hupert, Don Patterson, Jost Göttert, Robin L. McCarley, Dimitris Nikitopoulos, Michael C. Murphy and Steven A. Soper*
Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity Sensor. Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity Sensor.
Isolation of circulating tumor cells (CTCs) with our EasySep™ and RosetteSep™ cell separation platforms, provides high recovery of these rare cells from whole blood, buffy coat or mononuclear cell preparations. Enriched CTCs
Efficient Capture and Isolation of Tumor-Related Circulating Cell-Free DNA from Cancer Patients Using Electroactive Conducting Polymer Nanowire Platforms . SeungHyun Jeon 1,3*, HyungJae Lee 1,4,*, Kieun Bae 2, Kyong-Ah Yoon 2,5, Eun Sook Lee 1, Youngnam Cho 1 . 1.
Feb 12, 2013 Adams, A. A. et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics
Microdevices are disclosed to efficiently, accurately, and rapidly isolate and enumerate rare cells, such as circulating tumor cells, from liquids such as whole blood. The system employs multiple parallel meandering channels having a width on the order of 1-2 cell diameters. The microdevices can be produced at low-cost, may readily be automated, and in many instances may be used without pre
This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed.
Apr 24, 2018 This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed.
It is widely known that cells from epithelial tumors, e.g., breast cancer, detach from their primary tissue and enter blood circulation. We show that the presence of circulating tumor cells (CTCs) in samples of patients with primary and metastatic breast cancer can be detected with an array of selected tumor-marker-genes by reverse transcription real-time PCR.
The present study reports a new three-dimensional (3D) microfluidic platform capable of rapid isolation and detection of cancer cells from a large sample volume (e.g. ~1 mL) by utilizing magnetic
We show that the presence of circulating tumor cells (CTCs) in samples of patients with primary and metastatic breast cancer can be detected with an array of selected tumor-marker-genes by reverse transcription real-time PCR. reliable and highly efficient method. RNA Isolation Upon thawing, cell pellets were dissolved in 1 mL Trizol LS
The CTC microchips consisted of an architecture comprised of 50 sinusoidally-shaped channels that emanated from a common input and converged into a common output (see Adams et al., Highly Efficient Circulating Tumor Cell Isolation form Whole Blood and Label-Free Enumeration Using Polymer- based Microfluidics with an Integrated Conductivity
Sep 17, 2019 See A. Adams et al., “Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor,” J. Am. Chem. Soc., vol. 130, pp. 8633-8641 (2008), and the supporting material that is available at pubs.acs for additional details concerning the
Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics. MAJID EBRAHIMI WARKIANI. Andy Tay. Ali Bhagat. Lidan Wu. Bee
He is the founder and currently Chief Scientific Officer at BioFluidica, Inc., which is developing microfluidic platforms for the isolation of circulating tumor cells and Digital Nanogenetics, which is developing modular fluidic systems for disease detection and diagnosis.
This allowed processing large sample volumes in the microfluidic regime where picoliter samples volumes dominate high aspect ratio microstructures. This device was used to process mL scale volumes of fluid in a matter of minutes whereby circulating tumor cells were isolated from whole blood.
For example, we have previously demonstrated microfluidic cell isolation units for isolating extremely rare, circulating tumor cells from whole blood patient samples with high purity. 53,54 These microfluidic devices can be coupled to the μSPE device detailed in this manuscript to isolate plasma membrane proteins from these rare cells for
The incidence of these so-called “Circulating Tumor Cells” (CTCs) is linked to a worse prognosis for the patients’ survival time [7,8]. Thus, the detection of CTCs from peripheral blood samples could be a useful tool in diagnosis, prognosis and planning of further therapeutic steps.
The combination of computer simulations and experiments has given birth to a new generation of compact ICP torch with conical geometry, which offers superior analytical performance, a 50–70% savings in gas consumption, and a whole new level of analytical performance.
Although biomedical applications of carbon nanotubes have been intensively studied in recent years, its sister, graphene, has been rarely explored in biomedicine. In this work, for the first time we study the in vivo behaviors of nanographene sheets (NGS) with polyethylene glycol (PEG) coating by a fluorescent labeling method. In vivo fluorescence imaging reveals surprisingly high tumor uptake
Researchers Deliver Large Particles into Cells at High Speed Posted on April 9, 2015 by Admin A team led by Professor Eric Pei-Yu Chiou created a tool that delivers nanoparticles, enzymes, antibodies and bacteria into cells at the rate of 100,000 cells per minute —
Naturally occurring FOXP3 mutations provide unique opportunities to leverage clinical observations to increase our understanding of fundamental Treg cell biology. Van Gool et al. identify a mutation in the domain-swap interface of FOXP3 in IPEX patients and demonstrate a direct role for the mutant FOXP3 in reprogramming Treg cells to acquire a Th2-like phenotype, leading to Th2-mediated
Qian W, Wang J, Roginskaya V, McDermott LA, Edwards RP, Stolz DB, Llambi F, Green DR, Van Houten B. Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget. 2014 Jun 30;5(12):4180-94. doi: 10.18632/oncotarget.1944.
CENTER FOR CANCER RESEARCH Charlestown Laboratories Building 149, 13th Street Charlestown, MA 02129 Jackson Laboratories Jackson Building 55 Fruit Street Boston, MA 02114 Simches
Lab Chip, 2019, Accepted ManuscriptDOI: 10.1039/C9LC00874H, PaperZezheng Wu, Hongqiang Jiang, Lingling Zhang, Kezhen Yi, Heng Cui, Fubing Wang, Wei Liu, Xingzhong Zhao, Fuling Zhou, Shishang GuoThe research of circulating tumor cells (CTCs) is of great significance in cancer diagnosis, prognosis and even development of personalized therapy.
The three-dimensional folded structure of many coding and non-coding RNAs plays a key role in determining their function and fate in the cell. Obtaining high quality structural information on large numbers of RNAs is therefore essential, but traditional methods such as crystallography and NMR have been limited due to RNA's rugged folding
SESSION A FIFTH CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCESEPT. 25 28, 2019 PARIS, FRANCE 2 POSTER SESSION A Combination therapies with immune checkpoint
LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, Gelrud A, Anderson MA, Banks PA, Conwell D, Lawrence C, Romagnuolo J, Baillie J, Alkaade S, Cote G, Gardner TB, Amann ST, Slivka A, Sandhu B, Aloe A, Kienholz ML, Yadav D, Barmada MM, Bahar I, Lee MG, Whitcomb DC, North American Pancreatitis Study Group..Mechanisms of CFTR functional variants that impair regulated
35/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark limestoneas correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list,
Copyright © 2022 - All Rights Reserved